Judge won't toss off-label claims against Novartis; Pfizer dangles 5% premium for Zoetis share swap;

@FiercePharma: What we talk about when we talk about pharma. Commentary | Join our LinkedIn group | Follow @FiercePharma

@EricPFierce: Who manufacturers the top selling diabetes treatments? Novo has 5 of top 10 but not the top two. Special report | Follow @EricPFierce

> A federal judge said Novartis ($NVS) has to face whistleblower claims that it promoted off-label use, some of it known to be harmful, of its atopic dermatitis drug Elidel. Report

> The cost of specialty drugs will boost healthcare spending in the coming years, offsetting the savings from a dwindling supply of new generic launches, PricewaterhouseCoopers says. Report

> Pfizer ($PFE) is offering shareholders a 5% premium to exchange their stock for shares of its animal health company Zoetis as the drugmaker spins off its remaining stake. Report

> The Department of Health and Human Services Inspector General said Medicare should do more to investigate doctors who prescribe drugs in potentially questionable or harmful ways. Report

> Cases of the cancer-causing human papillomavirus (HPV) have plunged in girls and young women since Merck's ($MRK) Gardasil vaccine launched in 2006, a study found. Report

> A U.S. court determined that India's Zydus Cadila stepped on Takeda's patent for the drug Prevacid SoluTab. Report

Medical Device News

@FierceMedDev: Wright selling off hip and knee biz for $290M. Report | Follow @FierceMedDev

@DamianFierce: Japan's Terumo is adding 400+ jobs in an Irish R&D expansion. Yesterday's story | Follow @DamianFierce

@MichaelGFierce: Biosensor nanoparticles deliver cancer drug with precise, 3-D imaging. More | Follow @MichaelGFierce

> Brainsway partners up to push anti-depression tech in U.S. Article

> Mayo joins Sanovas to develop lung-clearing asthma treatment. Story

> Atossa teams with Thermo to market 'Pap smear for breast cancer.' News

Biotech News

@FierceBiotech: ICYMI this week's Industry Voices column - Ichorcumab: the blood of the gods? Feature | Follow @FierceBiotech

 @JohnCFierce: Sanofi - in need of some inspiration - partners with Curie Inst. on ovarian cancer targets. Release | Follow @JohnCFierce

@RyanMFierce: After Sanofi winds down manufacturing in Dagenham, U.K., what are the chances of a vibrant startup scene emerging there? More | Follow @RyanMFierce

 @EmilyMFierce: Biopharma tweeps, connect with colleagues and the editors of @FierceBiotech by joining our new LinkedIn group. | Follow @EmilyMFierce

> Cardio3 targets big cardio-drug market with small IPO. Item

> Biotech M&A buzz: Forest, others weigh offers for Elan. More

> PTC overcomes repeated setbacks to raise $125M in IPO. Report

> GlaxoSmithKline fuels VC fund as part of rare diseases blitz. Article

Vaccines News

> CDC finds vaccines halved HPV infections in teenage girls. Report

> GSK's rotavirus vaccine as effective as Merck shot. Item

> Tax loophole eyed ahead of launch of Sanofi, GSK, AstraZeneca quadrivalent shots. More

> HPV vaccine pioneer targeting skin cancer jab. Story

> Japan withdraws recommendation of Merck and GSK HPV jabs. Article

> CDC readies for 4-in-1 flu vaccines. More

Pharma Manufacturing News

> GSK, Pfizer help start effort researching manufacturing innovations. Story

> Brazil to build Protalix a plant as part of sophisticated tech transfer. News

> Sanofi plant in London set to close by end of month. Article

> Gilead recalls 20 batches of AmBisome due to possible contamination. Report

And Finally... A respiratory virus that recently emerged in Saudi Arabia spread with chiling ease to ill patients in the hospital, an investigation found. Report

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.